Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024


Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, before the opening of the market on Friday, February 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com.

The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram


These press releases may also interest you

at 14:11
Brains is proud to be Certifiedtm by Great Place To Work® for the 7th year in a row. The prestigious award is based entirely on what current employees say about their experience working at Brains....

at 14:05
Joseph Petrelli, President, Demotech, Inc., who authorized and initiated Demotech's ground-breaking research project in March 2022 notes with pride,  "Demotech's research, undertaken by Todd Kozikowski, identified the business model that exacerbates...

at 14:05
Rise48 Equity, a leading multifamily investment group, recently announced their recent acquisitions of W Flats Apartments (247 units) and Matthews Pointe Apartments (100 units) in Charlotte, NC. Both properties will be rebranded to "Rise Blue Ridge"...

at 14:00
The new logo and visual identity for Calgary's civic brand, Blue Sky City, will be shared with the community at First Flip ? the first official Stampede event of the year. The visual identity was inspired by beadwork which captures Calgary's story as...

at 13:51
Trading resumes in: Company: Bedford Metals Corp. TSX-Venture Symbol: BFM All Issues: No Resumption (ET): 1:36: 30 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading...

at 13:46
K1 Investment Management ("K1"), one of the largest small-cap enterprise software investment firms, yesterday completed the sale of its portfolio company GoCanvas®. GoCanvas, a leading field worker collaboration software provider, was acquired by...



News published on and distributed by: